152 related articles for article (PubMed ID: 37800725)
1. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
[No Abstract] [Full Text] [Related]
2. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
[TBL] [Abstract][Full Text] [Related]
3. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy.
Jang SY; Park SJ; Chae MK; Lee JH; Lee EJ; Yoon JS
Br J Ophthalmol; 2018 Mar; 102(3):407-414. PubMed ID: 29101123
[TBL] [Abstract][Full Text] [Related]
4. Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves' Ophthalmopathy by Targeting Orbital Fibroblasts.
Yang S; Wang X; Xiao W; Xu Z; Ye H; Sha X; Yang H
Front Endocrinol (Lausanne); 2022; 13():891922. PubMed ID: 35663306
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine-1-Phosphate Mediates Fibrosis in Orbital Fibroblasts in Graves' Orbitopathy.
Ko J; Chae MK; Lee JH; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2017 May; 58(5):2544-2553. PubMed ID: 28492873
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of Targeting Periostin in the Treatment of Graves' Orbitopathy.
Jang SY; Kim J; Park JT; Liu CY; Korn BS; Kikkawa DO; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2022; 13():900791. PubMed ID: 35707463
[TBL] [Abstract][Full Text] [Related]
7. Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy.
Jang SY; Choi SH; Kikkawa D; Lee EJ; Yoon JS
PLoS One; 2021; 16(8):e0255344. PubMed ID: 34383782
[TBL] [Abstract][Full Text] [Related]
8. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy.
Yoon JS; Chae MK; Jang SY; Lee SY; Lee EJ
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5921-9. PubMed ID: 22871832
[TBL] [Abstract][Full Text] [Related]
9. M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor.
Lu Y; Wang Y; Wang Y; Wu Y; Huang Y; Liu X; Zhang S; Zhong S; Li Y; Li B; Sun J; Fang S; Zhou H
Thyroid; 2023 Mar; 33(3):338-350. PubMed ID: 36617890
[No Abstract] [Full Text] [Related]
10. Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
Wang X; Yang S; Ye H; Chen J; Shi L; Feng L; Wang X; Zhang T; Chen R; Xiao W; Yang H
Thyroid; 2022 Mar; 32(3):294-305. PubMed ID: 34605662
[No Abstract] [Full Text] [Related]
11. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
[TBL] [Abstract][Full Text] [Related]
12. Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Lee CE; Choi SH; Yoon JS
Korean J Ophthalmol; 2020 Jun; 34(3):192-202. PubMed ID: 32495527
[TBL] [Abstract][Full Text] [Related]
13. Role of miR-146a in the Regulation of Inflammation in an In Vitro Model of Graves' Orbitopathy.
Jang SY; Chae MK; Lee JH; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2016 Aug; 57(10):4027-34. PubMed ID: 27494344
[TBL] [Abstract][Full Text] [Related]
14. High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy.
Han SY; Choi SH; Shin JS; Lee EJ; Han SH; Yoon JS
Thyroid; 2019 Jun; 29(6):868-878. PubMed ID: 30973094
[No Abstract] [Full Text] [Related]
15. Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients.
Ekronarongchai S; Palaga T; Saonanon P; Pruksakorn V; Hirankarn N; van Hagen PM; Dik WA; Virakul S
Thyroid; 2021 Oct; 31(10):1566-1576. PubMed ID: 34235979
[No Abstract] [Full Text] [Related]
16. Immunophenotype of Lacrimal Glands in Graves Orbitopathy: Implications for the Pathogenesis of Th1 and Th17 Immunity.
Huang Y; Wu Y; Zhang S; Lu Y; Wang Y; Liu X; Zhong S; Wang Y; Li Y; Sun J; Fang S; Zhou H
Thyroid; 2022 Aug; 32(8):949-961. PubMed ID: 35469435
[No Abstract] [Full Text] [Related]
17. Molecular biomarkers of Graves' ophthalmopathy.
Longo CM; Higgins PJ
Exp Mol Pathol; 2019 Feb; 106():1-6. PubMed ID: 30414981
[TBL] [Abstract][Full Text] [Related]
18. Curcumin Suppresses TGF-β1-Induced Myofibroblast Differentiation and Attenuates Angiogenic Activity of Orbital Fibroblasts.
Yu WK; Hwang WL; Wang YC; Tsai CC; Wei YH
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202024
[TBL] [Abstract][Full Text] [Related]
19. Ceruloplasmin regulating fibrosis in orbital fibroblasts provides a novel therapeutic target for Graves' orbitopathy.
Cao J; Qi X; Wang N; Chen Y; Xie B; Ma C; Chen Z; Xiong W
J Endocrinol Invest; 2023 Oct; 46(10):2005-2016. PubMed ID: 36849849
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
Byeon HJ; Kim JY; Ko J; Lee EJ; Don K; Yoon JS
PLoS One; 2020; 15(8):e0237015. PubMed ID: 32760098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
